-
Polasek TM, Sadagopal JS, Elliot DJ & Miners JO
Jan 2010
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
European Journal of Clinical Pharmacology
In Press, December 2009.
More info
-
Jornil J, Jensen KG, Larsen F and Linnet K
Jan 2010
Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism using a Population-Based Simulator.
Drug Metabolism & Disposition
In Press, 2010.
More info
-
Berry LM, Roberts J, Be X, Zhao Z & Lin MH
Dec 2009
Prediction of Vss from in vitro tissue binding studies.
Drug Metabolism & Disposition
In Press, October 2009.
More info
-
Wong H, Chen JZ, Chou B, Halladay JS, Kenny JR, La H, Marsters JC Jr, Plise E, Rudewicz PJ, Robarge K, Shin Y, Wong S, Zhang C & Khojasteh SC
Dec 2009
Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Xenobiotica
39(11), 850-861, November 2009.
More info
-
Xu L, Chen Y, Pan Y, Skiles GL & Shou M
Dec 2009
Prediction of human drug and drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Drug Metabolism & Disposition
37(12), 2330-2339, December 2009..
More info
-
Caldwell GW, Yan Z, Tang W, Dasgupta M & Hasting B
Nov 2009
ADME optimization and toxicity assessment in early- and late-phase drug discovery.
Current Topics in Medicinal Chemistry
9(11), 965-980, 2009.
More info
-
Polasek TM, Polak S, Doogue MP, Rostami-Hodjegan A & Miners JO
Oct 2009
Assessment of inter-individual variability in predicted phenytoin clearance.
European Journal of Clinical Pharmacology
65(12), 1203-1210, December 2009.
More info
-
Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I & Watelet JB
Oct 2009
Physiologically based pharmacokinetics (PBPK).
Drug Metabolism Reviews
41(3), 391-407, 2009.
More info
-
de Groot MJ, Wakenhut F, Whitlock G & Hyland R
Oct 2009
Understanding CYP2D6 interactions.
Drug Discovery Today
14(19-20), 964-972, October 2009.
More info
-
Foti RS, Pearson JT, Rock DA, Wahlstrom JL & Wienkers LC
Sep 2009
In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract.
Drug Metabolism & Disposition
37(9), 1848-1855, September 2009.
More info
-
Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R & Obach RS
Aug 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Drug Metabolism & Disposition
37(8), 1658-1666, August 2009.
More info
-
Gibson CR, Bergman A, Lu P, Kesisoglou F, Denney WS & Mulrooney E
Aug 2009
Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling.
Xenobiotica
39(9), 637-648, September 2009.
More info
-
Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ & Obach RS
Jul 2009
The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Drug Metabolism & Disposition
37(7), 1355-1370, July 2009.
More info
-
Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M
Jul 2009
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.
Drug Metabolism & Disposition
37(7), 1339-1354, July 2009.
More info
-
Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K & Jones B
Apr 2009
In vitro and in vivo glucuronidation of midazolam in humans.
British Journal of Clinical Pharmacology
67(4), 445-454, April 2009.
More info
-
Emoto C, Murayama N, Rostami-Hodjegan A & Yamazaki H
Mar 2009
Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding.
Xenobiotica
39(3), 227-235, March 2009.
More info
-
Summerfield S & Jeffrey P
Mar 2009
Discovery DMPK: changing paradigms in the eighties, nineties and noughties.
Expert Opinion on Drug Discovery
4(3), 207-218, 2009.
More info
-
Thelingwani RS, Zvada SP, Hugues D, Ungell AL & Masimirembwa CM
Mar 2009
In vitro and in silico identification and characterisation of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.
Drug Metabolism & Disposition
37(6), 1286-1294, June 2009.
More info
-
Badwan A, Remawi M, Qinna N, Elsayed A, Arafat T, Melhim M, Hijleh OA & Idkaidek NM
Mar 2009
Enhancement of oral bioavailability of insulin in humans.
Neuro Endocrinology Letters
30(1), 74-78, March 2009.
More info
-
Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE & Huang SM
Feb 2009
Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
Journal of Clinical Pharmacology
49(3), 351-359, March 2009.
More info
-
Grime KH, Bird J, Ferguson D & Riley RJ
Feb 2009
Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
European Journal of Pharmaceutical Sciences
36(2-3), 175-191, February 2009.
More info
-
Bouzom F & Walther B
Dec 2008
Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
Fundamentals of Clinical Pharmacology
22(6), 579-587, December 2008.
More info
-
Hyland R, Dickins M, Collins C, Jones H & Jones B
Oct 2008
Maraviroc: in vitro assessment of drug-drug interaction potential.
British Journal of Clinical Pharmacology
66(4), 498-507, October 2008.
More info
-
Westerhoff HV, Mosekilde E, Noe CR & Clemensen AM
Sep 2008
Integrating systems approaches into pharmaceutical sciences.
European Journal of Pharmaceutical Sciences
35(1-2), 1-4, September 2008.
More info
-
Karalis V, Macheras P, Van Peer A & Shah VP
Aug 2008
Bioavailability and bioequivalence: focus on physiological factors and variability.
Pharmaceutical Research
25(8), 1956-1962, August 2008.
More info
-
Fowler S & Zhang H
Jun 2008
In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.
The AAPS Journal
10(2), 410-424, June 2008.
More info
-
McGinnity DF, Waters NJ, Tucker J & Riley RJ
Jun 2008
Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
Drug Metabolism & Disposition
36(6), 1126-1134, June 2008.
More info
-
Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F & Obach RS
May 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
British Journal of Clinical Pharmacology
65(5), 680-692, May 2008.
More info
-
Dong JQ, Chen B, Gibbs MA, Emery M, & Gibbs JP
Mar 2008
Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration.
Current Computer-Aided Drug Design
4(1), 54-66, March 2008.
More info
-
Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL & Slatter JG
Mar 2008
Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.
Xenobiotica
38(3), 264-280, March 2008.
More info
-
Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL & Hamilton M
Jan 2008
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (Simcyp) predicts in vivo metabolic inhibition.
European Journal of Clinical Pharmacology
64(1), 31-41, January 2008.
More info
-
De Buck SS & Mackie CE
Dec 2007
Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
Expert Opinion on Drug Metabolism & Toxicology
3(6), 865-878, December 2007.
More info
-
Einolf HJ
Oct 2007
Comparison of different approaches to predict metabolic drug-drug interactions.
Xenobiotica
37(10-11), 1257-1294, October-November 2007.
More info
-
Riley RJ, Grime K & Weaver R
Feb 2007
Time-dependent CYP inhibition.
Expert Opinion on Drug Metabolism & Toxicology
3(1), 51-66, February 2007.
More info
-
Ekins S, Nikolsky Y & Nikolskaya T
Apr 2005
Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity.
Trends in Pharmacological Science
26(4), 202-209, April 2005.
More info
-
Wishart DS
Mar 2005
Bioinformatics in drug development and assessment.
Drug Metabolism Reviews
37(2), 279-310, 2005.
More info